Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PP1131 bacteriophage cocktail
- Development stage
- Unknown
- Lead developer
- PHAXIAM Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
PP1131 bacteriophage cocktail is a biologic therapeutic consisting of 12 natural lytic bacteriophages specifically targeting *Pseudomonas aeruginosa*. Developed by Pherecydes Pharma (now Phaxiam Therapeutics), it was designed for the topical treatment of infected burn wounds. The mechanism of action involves the phages' ability to recognize and bind to specific receptors on the surface of *P. aeruginosa*, inject their genetic material, and replicate within the host cell, leading to bacterial cell lysis and death. This process involves the disruption of the bacterial cell wall and membrane. PP1131 was the subject of the PHAGOBURN trial (NCT02116010), a Phase I/II multicenter study that represented one of the first international randomized controlled trials of phage therapy conducted under modern regulatory standards.
- Other names
- P. aeruginosa phages cocktail – PherecydesPHAGOBURN Pseudomonas phage therapy – Pherecydes
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on PP1131 bacteriophage cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PP1131 bacteriophage cocktail.